Loading clinical trials...
Loading clinical trials...
Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma
Conditions
Interventions
Intra-arterial Cetuximab
Intra-arterial Mannitol
+1 more
Locations
1
United States
Lenox Hill Brain Tumor Center
New York, New York, United States
Start Date
May 1, 2016
Primary Completion Date
May 1, 2035
Completion Date
May 1, 2036
Last Updated
April 13, 2026
NCT05969860
NCT05789394
NCT06860594
NCT00083512
NCT05839379
NCT07225621
Lead Sponsor
Northwell Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions